# US 11,026,950 B2 · Methods and compositions for treating mesothelioma and small lung cancer that express midkine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,026,950 B2
- Document ID: US11026950B2
- Status: Granted
- Kind: B2
- Application number: 16/857,285
- Filed: 2020-04-24
- Published: 2020-09-03
- Granted: 2021-06-08
- Earliest claimed: 2016-07-28
- Assignees: Children's Hospital Medical Center
- Applicants: Children's Hospital Medical Center
- Inventors: Jeffrey A. Whitsett; Yutaka Maeda; Takuya Fukazawa
- Web page: https://patentgrep.com/patent/US11026950B2

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.

## Claims

### Claim 1

A method of treating malignant mesothelioma, comprising the step of administering to an individual in need thereof, an effective amount of a pharmaceutical composition comprising a compound selected from
or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein said compound is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound is administered with

### Claim 4 (depends on 1)

The method of claim 1, further comprising the step of administering to said individual a therapeutically effective amount of a BCL-2 inhibitor.

### Claim 5 (depends on 1)

The method of claim 1, wherein said individual is mammalian.

### Claim 6 (depends on 1)

The method of claim 1, wherein said individual is human.

### Claim 7 (depends on 4)

The method of claim 4, wherein said BCL-2 inhibitor is selected from ABT-737, ABT-199, GDC-0199, GX15-070 (Obatoclax), and combinations thereof.